Professors Bin Song & Yuan Peng: How Should We Choose CDK4/6 Inhibitors for Adjuvant Endocrine Therapy Intensification?

Professors Bin Song & Yuan Peng: How Should We Choose CDK4/6 Inhibitors for Adjuvant Endocrine Therapy Intensification?

For patients with hormone receptor–positive (HR+) early breast cancer, when intensifying adjuvant endocrine therapy with a CDK4/6 inhibitor, should abemaciclib or ribociclib be preferred? At the 2025 Summer Breast Cancer Forum · Northern Salon, Professors Bin Song of Shanxi Bethune Hospital and Yuan Peng of Peking University People’s Hospital debated this question during the “Debate” session. Here, in Oncology Frontier’s “In-Depth” column, they share their perspectives supported by evidence.
The 28th CSCO Annual Meeting Opens in Jinan

The 28th CSCO Annual Meeting Opens in Jinan

This September, the city of Jinan welcomed one of China’s most prestigious academic events in oncology. The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2025) officially opened on the morning of September 11th, gathering experts, clinicians, researchers, and industry representatives from across the country. Multiple academicians and internationally renowned oncologists attended the ceremony to discuss new progress in cancer prevention and treatment under the theme “Standardized Treatment, Innovation-Driven Leadership”—together charting a new global blueprint for the fight against cancer.
Professors Ning Xie & Lingzhi Xu: ADC vs. Targeted Therapy + Endocrine Therapy in the Post-CDK4/6i Era

Professors Ning Xie & Lingzhi Xu: ADC vs. Targeted Therapy + Endocrine Therapy in the Post-CDK4/6i Era

For patients with hormone receptor–positive (HR+) advanced breast cancer who progress after treatment with CDK4/6 inhibitors, should clinicians choose antibody–drug conjugates (ADCs) or a combination of targeted therapy plus endocrine therapy (ET)? At the 2025 Summer Breast Cancer Forum · Northern Salon, the “Debate” session addressed this very question. Professor Ning Xie of Hunan Cancer Hospital and Professor Lingzhi Xu of the Second Affiliated Hospital of Dalian Medical University presented evidence-based arguments for ADCs and for targeted therapy + ET, respectively. In this Oncology Frontier feature, they further elaborate on their viewpoints.